VISUSTRIN COLL 10ML 1MG/ML

VISUTRIN 1 MG/ML COLLIRIC DEOLUTION

active ingredients

10 ml of eye drops contain: Active ingredient: tetrizolina hydrochloride 10 mg. For the full list of excipients, see paragraph 6.1.

Excellent

Excipients: boric acid; chloride sodium; borace; benzalconio chloride; sodium edetate; purified water.

Therapeutic indications

Hyperemies, itching, burning, joint edema.

Contraindications

• Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1. VISUSTRIN should not be used by subjects with glaucoma or other serious eye diseases and children under three years.

Population

Posology Apply 2 drops in each eye two or three times a day. Do not exceed the recommended doses.

Conservation

To be stored at a temperature not exceeding 25 °C.

Warnings

In case of persistence or aggravation of symptoms after a short period of treatment, consult your doctor; in any case, the product should not be used for more than four consecutive days, given the possibility that side effects may occur. Infections, pus, foreign bodies in the eye, mechanical, chemical, heat damage, require the attention of the doctor. The product, while presenting a poor systemic absorption, should be used with caution in patients suffering from hypertension, hyperthyroidism, heart disorders and hyperglycemia (diabetes) and in patients undergoing treatment with antidepressant drugs. For those who carry out sports activities: the use of the drug without need constitutes doping and can determine however positivity to anti-doping tests. It can cause irritation to the eyes. Avoid contact with soft contact lenses. Remove contact lenses before application and wait at least 15 minutes before reapplying them. It is known the decoloring action against soft contact lenses. Strictly adhere to the recommended doses. The product if accidentally ingested or if used for a long period at excessive doses may cause toxic phenomena. Do not obtain relief within 48 hours from the beginning of treatment, suspend use and carry out an accurate ophthalmological examination. Pediatric population VISUSTRIN must be kept away from the reach of children as accidental ingestion can cause severe sedation. Safety and effectiveness in children have not been established. Use in children over three years of age must be evaluated by the doctor.

Interactions

Not known.

Effects

The use of VISUSTRIN can sometimes determine pupilal dilation, systemic effects of absorption (hypertension, heart disorders, hyperglycemia), increased blood pressure, nausea, headache. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare professionals are required to report any adverse reaction suspected through the national reporting system of the Italian Pharmaco Agency at: http://www.agenziafarmaco.gov.it/it/responsabili

Overdosing

In case of overdose, suspend treatment and start suitable therapy.

In pregnant women or during breastfeeding, the medicine should be administered in cases of actual need, under the direct control of the doctor.

Source: Farmadati